CompletedPhase 3NCT02108860
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of South Florida
- Principal Investigator
- Carol A Langford, MD, MHS, MDThe Cleveland Clinic
- Intervention
- Abatacept(drug)
- Enrollment
- 65 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2015 – 2023
Study locations (20)
- Cedars Sinai Medical Center, Los Angeles, Los Angeles, California, United States
- University of South Florida Rheumatology, Tampa, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Hospital for Special Surgery, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- Vanderbilt University, Nashville, Tennessee, United States
- University of Calgary, Calgary, Alberta, Canada
- University of British Columbia, St. Paul's Rheumatology Clinic, Vancouver, British Columbia, Canada
- St. Joseph's Hospital, Hamilton, Hamilton, Ontario, Canada
- Mount Sinai Hospital, Toronto, Toronto, Ontario, Canada
- Medius Kliniken, Kirchheim unter Teck, Germany
- +5 more locations on ClinicalTrials.gov
Collaborators
The Cleveland Clinic · Bristol-Myers Squibb · University of Pennsylvania · National Institutes of Health (NIH) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02108860 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →